Dr. Jiahai SHI
Jiahai SHI, Ph.D.
2021 – Presence:
Assistant professor at Department of Biochemistry, National University of Singapore.
Principle Investigator, NUS Medicine Synthetic Biology Translational Research Programme.
2015 – 2021 Assistant/Associate Professor, City University of Hong Kong
2010 – 2015 Postdoctoral Fellow, Whitehead Institute for Biomedical Research, MIT
2008 – 2010 Research Fellow, National University of Singapore
Publications
Scopus Citations
H-index
Patents
EDUCATION AND RESEARCH
Whitehead Institute for Biomedical Research / Massachusetts Institute of Technology, Cambridge, MA
- Postdoctoral Fellow, Advisor: Dr. Harvey Lodish, 2010 – 2015
- Topic: Understanding and engineering red blood cells for intravascular drug delivery
National University of Singapore, Singapore
- Ph.D., Biochemistry and Biophysics, 2008
- Graduate research, Advisor: Dr. Jianxing Song, 2003 – 2008
- Thesis: Structural study revealing the unique enzymatic mechanism of the Severe Acute Respiratory Syndrome (SARS) coronavirus main protease highly mediated by the extra domain
Xiamen University, P. R. China
- B.Sc., Biology, 2002
- Undergraduate research with Dr. Ningshao Xia, 2001 – 2002
- Topic: Cloning Hepatitis C Virus E1 & E2 genes from the serum of infected patients, and expression of truncated E1 & E2 proteins for anti-Hepatitis C Virus vaccine development
FUNDING
2018-2023: Blood type determination by high throughput sequencing.
2019-2022: Gene therapies targeting BCL11A for beta-thalassemia treatment development.
2019-2022: Investigating the function of Spleen Tyrosine Kinase (Syk) as an important regulator of terminal erythropoiesis.
2018-2020: Engineering red blood cells for the delivery of metabolic enzymes against Niemann-Pick disease and other sphingolipidoses.
2018-2021: The study of ROS mediated Syk signaling in erythroid terminal development.
2017-2020: The study of shark single domain antibodies.
2017-2020: The study of in vitro synthesis of long RNA by novel RNA polymerase.
PATENTS
High-affinity anti-EGFP and anti-SARS-CoV-2 vNAR single domain antibodies and use thereof.
SURFACE MODIFIED RED BLOOD CELLS AND METHODS OF GENERATING THE SAME.
A robotic device.
Specific primer pairs designed for single variable new antigen receptor domain derived from IgNAR of Chiloscyllium plagiosum.
METHOD OF MODIFYING SURFACE OF EXTRACELLULAR VESICLE.
Modified Protein and Method for Altering Genome of Cell.
Method of Producing Antibody Fragment.
Isolation of extracellular vesicles from red blood cells for gene therapy.
IN VITRO PRODUCTION OF RED BLOOD CELLS WITH SORTAGGABLE PROTEINS.
ENTREPRENEURSHIP
2021-present: Set up Carcell Biopharma with EVX Venture at Shanghai with US$16 million investment
2021-present: Set up Jotbody (HK) for camel and shark single domain antibody service, and join Hong Kong Science Park incu bio program.
2019-present: Working with EVX venture as a co-founder to set up Carmine Therapeutics in Boston and Singapore (Raised 9.4 million US dollars), which won “Golden Tickets” from Bristol-Myers Squibb in 2019. Carmine therapeutic forms an agreement with Takeda to co-develop 2 gene therapies with a total value at US$ 900 million.
2013-2015 Working with Flagship venture in the early stage of Rubius Therapeutics (IPOed in 2018) in Boston.
2015 Oct. 23: First prize in 10th Chunhui Cup Contest and Innovation & Entrepreneurship competition (East America District) (RNASyn).
AWARDS AND SCHOLARSHIPS
The Team (Alumni) Award.
Shortlisted for Nanyang Assistant Professorship (S$1 million).
Whitehead Institute Postdoc Association Education Award.
National University of Singapore Research Scholarship.
Scholarship for the Novartis International Biotechnology Leadership Camp, Singapore, and the first team prize in a business proposal competition at the camp.
2nd best Oral Presentation Award.
CONFERENCE PRESENTATIONS (Oral)
Engineered red blood cell extracellular vesicles for targeted RNA delivery.
From Rubius to Carmine and Carcell, how does basic scientific research transform into industry?
Genetically engineered Red Blood Cells for targeted drug deliveries.
Genetically-modified Red Blood Cells (RBCs) against anemia, metabolic disorders and cancers in future.
SYMPOSIUM ON “REPARATIVE MEDICINE AND BEYOND”, “Engineered Red Blood Cells for targeted drug deliveries”.
Shark single domain antibodies turn red blood cells into therapeutic agents.
JAK2-V617F enhances red cell production by triggering CFU-E self-renewal.
The Catalysis of the Severe Acute Respiratory Syndrome (SARS) 3C-Like Protease is controlled by its C-terminal extra domain remotely’, (2nd best Oral Presentation Award).
TEACHING EXPERIENCE
Teaching BMS3001-Hematology and BMS3006-Blood transfusion (course leaders) with a teaching evaluation score 6.4 out of 7.
Teaching BMS3002-Advanced Cellular Pathology, and BMS8106- Stem Cell and Regenerative Medicine, with a teaching evolution score 6.8 out of 7.
Mentoring 11 graduate students in City University of Hong Kong (2015-present).
Mentoring 1 graduate student (Novalia Pishesha) in the Lodish lab at the Whitehead Institute (2010-2015).
Mentoring 2 undergraduate students (Katherline Luo, and Heejo Choi) in the Lodish lab at the Whitehead Institute (2010-2015).
Mentored 2 undergraduate students (Shixiong Lua, and Dr. Miaoqing Fang) in the Song lab at National University of Singapore (2003-2010).
Mentored 4 undergraduates in the Special Program of Science, Faculty of Science, National University of Singapore (Jan. 2006 – May 2006).
Teaching assistant in General Biology at Department of Biological Sciences, National University of Singapore (Jan. 2004 – Dec. 2005).
PROFESSORAL SERVICES
Being a reviewer for TR35 Asian 2021.
Science advisor of Shenzhen Blood Center for comprehensive identification of blood types by high-through-put sequencing (2018-2023).
Translator and auditor for the translation of Chinese scientific publications in China National Knowledge Infrastructure (CNKI) (2015).
